| The influence of cyclic hormonal contraception on expression of premenstrual syndrome KA Yonkers, B Cameron, R Gueorguieva, M Altemus, SG Kornstein Journal of women's health 26 (4), 321-328, 2017 | 32 | 2017 |
| Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activity K Shinoda, R Li, A Rezk, I Mexhitaj, KR Patterson, M Kakara, L Zuroff, ... Proceedings of the National Academy of Sciences 120 (3), e2207291120, 2023 | 22 | 2023 |
| Demographic, spatial and temporal dietary intake patterns among 526 774 23andMe research participants JF Shelton, B Cameron, S Aslibekyan, R Gentleman, ... Public Health Nutrition 24 (10), 2952-2963, 2021 | 10 | 2021 |
| Extensions to the two‐stage randomized trial design for testing treatment, self‐selection, and treatment preference effects to binary outcomes B Cameron, P Peduzzi, D Esserman Statistics in Medicine 37 (22), 3147-3178, 2018 | 10 | 2018 |
| Sample size and power for a stratified doubly randomized preference design B Cameron, DA Esserman Statistical Methods in Medical Research 27 (7), 2168-2184, 2018 | 10 | 2018 |
| Two‐stage randomized trial design for testing treatment, preference, and self‐selection effects for count outcomes Y Shi, B Cameron, X Gu, M Kane, P Peduzzi, DA Esserman Statistics in Medicine 39 (25), 3653-3683, 2020 | 6 | 2020 |
| On weighted composite scores for early Alzheimer's trials K Jin, B Cameron, B Dunn Pharmaceutical Statistics 18 (2), 239-247, 2019 | 5 | 2019 |
| Prevalence and progression of macular atrophy in eyes with neovascular age-related macular degeneration in the phase 2 Ladder trial of the port delivery system with ranibizumab GJ Jaffe, B Cameron, D Kardatzke, J Ives, G Barteselli, S Gune Ophthalmology Retina 6 (9), 786-795, 2022 | 4 | 2022 |
| Emerging cerebrospinal fluid biomarkers of disease activity and progression in multiple sclerosis AH Cross, JM Gelfand, S Thebault, JL Bennett, HC Von Büdingen, ... JAMA neurology 81 (4), 373-383, 2024 | 1 | 2024 |
| Large-scale trans-ethnic replication and discovery of genetic associations for rare diseases with self-reported medical data SS Shringarpure, W Wang, Y Jiang, A Acevedo, D Dhamija, B Cameron, ... MedRxiv, 2021.06. 09.21258643, 2021 | 1 | 2021 |
| preference: An R package for two-stage clinical trial design accounting for patient preference B Cameron, MJ Kane, D Esserman Journal of Statistical Software 94, 1-16, 2020 | 1 | 2020 |
| Mobile apps versus web browsers: A comparison of self-administered survey platforms B Cameron, 23andMe Research Team, R Gentleman CHANCE 31 (4), 29-36, 2018 | 1 | 2018 |
| Feasibility of neurofilament light chain as a blood-based biomarker for screening across neurological diseases B Cameron, A Patel, B Cobb, I Suridjan, N Win Journal of the Neurological Sciences 455, 121474, 2023 | | 2023 |
| Multiple sclerosis: a path to unravelling disease complexity with multidimensional quantitative analytics using digital tools for phenotyping spatiotemporal gait and cognition O Kaczmarek, S Baek, J Weller, B Cameron, C Cousin, ES Mearns, ... MULTIPLE SCLEROSIS JOURNAL 29, 741-742, 2023 | | 2023 |
| Reduction of intrathecal immunoglobulin levels with ocrelizumab treatment in relapsing and primary progressive multiple sclerosis M Weber, J Gelfand, A Bar-Or, B Cameron, A Ramesh, V Anania, ... MULTIPLE SCLEROSIS JOURNAL 29, 570-571, 2023 | | 2023 |
| Feasibility of Neurofilament Light Chain as a Blood-Based Biomarker for Screening Across Neurological Diseases (P10-6.002) B Cameron, A Patel, B Cobb, I Suridjan, N Win Neurology 100 (17 Supplement 2), 2023 | | 2023 |
| Package ‘preference’ B Cameron, D Esserman, M Kane, MM Kane | | 2022 |
| Identification of Novel CSF Measures of Disease Activity and Chronic Progressive Biology in MS: Results of the Ocrelizumab Biomarker Outcome Evaluation Study (OBOE): An Open … AH Cross, JM Gelfand, JL Bennett, HC von Büdingen, B Cameron, ... MULTIPLE SCLEROSIS JOURNAL 28 (3_ SUPPL), 443-444, 2022 | | 2022 |
| Cellular immune profiling pre-and post-aCD20 therapy points to differential effects on CD4 (+) and CD8 (+) T cells and implicates CD20-expressing CD8 (+) T cells in MS disease … K Shinoda, R Li, A Rezk, I Mexhitaj, KR Patterson, M Kakara, L Zuroff, ... | | 2021 |
| Extending the two-stage patient preference design for binary outcomes with stratification D Esserman, B Cameron, P Peduzzi TRIALS 18, 2017 | | 2017 |
Ralitza GueorguievaYale UniversityVerified email at yale.edu
